Sharemaestro company-news research for Adlai Nortye Ltd. American Depositary Shares (ANL), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.

NASDAQ United States Provisional evidence

Company news sentiment

Latest ANL news and sentiment

Adlai Nortye Ltd. American Depositary Shares

Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.

Full chart Weekly report Factor research RSS feed
30-day score52Neutral is 50
Early balanced news score 20/100 evidence confidence 100% direct company focus 17 current stories across 4 publishers
Latest weekly closeUSD 15.74week of 18 Sep 2026
Main news subjectMarket update75/100 share of current news
News data statusHealthy20 duplicate stories removed

Current company news

Early balanced news score

17 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.

Observed headline tone75/100 Published 30-day score52/100

Older, less relevant and less reliable stories count for less. Confidence is shown separately.

Latest source headline Adlai Nortye (NASDAQ: ANL) director lines up ADS sale Stock Titan · 18 Sep 2026 15:10

What supports the score

Direct evidence

17 current stories are mapped specifically to ANL.

Source breadth

The score uses 4 publishers rather than depending on one outlet.

What limits the score

Too little evidence

The stories agree, but freshness-weighted evidence is only 0.089.

Confidence

Confidence is 20/100, below the threshold for a firm score.

52/100
News scoreEarly balanced news score
20/100
Confidencethin evidence
100%/100
Company news17 company stories
95/100
Story agreement5/100 difference

News history

Daily score and story count over 30 days

Daily weighted evidence
23 Aug: 1 stories26 Aug: 1 stories27 Aug: 1 stories28 Aug: 1 stories05 Sep: 1 stories08 Sep: 3 stories10 Sep: 1 stories11 Sep: 1 stories15 Sep: 1 stories16 Sep: 2 stories18 Sep: 1 stories 23 Aug: tone 47, 1 stories26 Aug: tone 50, 1 stories27 Aug: tone 61, 1 stories28 Aug: tone 42, 1 stories05 Sep: tone 50, 1 stories08 Sep: tone 59, 3 stories10 Sep: tone 77, 1 stories11 Sep: tone 50, 1 stories15 Sep: tone 50, 1 stories16 Sep: tone 50, 2 stories18 Sep: tone 50, 1 stories 95505
23 Aug07 Sep21 Sep
News scoreStory count50 baseline

Confidence

How reliable the score is

Separate from direction

Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.

Amount of evidence2
0.089 after freshness weighting
Source breadth80
4 independent publishers
Company relevance100
share tied directly to this company
Freshness28
recency-weighted evidence
Agreement95
how closely stories agree
Publisher mix21
less reliance on one publisher

Price and news history

Weekly price and news-score history

Early company-news score

Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.

26 completed price weeks24 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
27 Mar 2026: close 6.46, indexed 100.003 Apr 2026: close 8.18, indexed 126.610 Apr 2026: close 11.16, indexed 172.817 Apr 2026: close 16.01, indexed 247.824 Apr 2026: close 14.8, indexed 229.101 May 2026: close 15.5, indexed 239.908 May 2026: close 13.28, indexed 205.615 May 2026: close 13.51, indexed 209.122 May 2026: close 11.92, indexed 184.529 May 2026: close 11.94, indexed 184.805 Jun 2026: close 9.95, indexed 154.012 Jun 2026: close 10.32, indexed 159.819 Jun 2026: close 10.1, indexed 156.326 Jun 2026: close 10.0, indexed 154.803 Jul 2026: close 9.49, indexed 146.910 Jul 2026: close 9.87, indexed 152.817 Jul 2026: close 11.53, indexed 178.524 Jul 2026: close 12.5, indexed 193.531 Jul 2026: close 13.0, indexed 201.207 Aug 2026: close 13.28, indexed 205.614 Aug 2026: close 13.25, indexed 205.121 Aug 2026: close 13.7, indexed 212.128 Aug 2026: close 13.82, indexed 213.904 Sep 2026: close 15.01, indexed 232.411 Sep 2026: close 15.21, indexed 235.418 Sep 2026: close 15.74, indexed 243.7 27 Mar 2026: news score 50, close 6.46, 1 stories5003 Apr 2026: news score 50, close 8.18, 1 stories10 Apr 2026: news score 50, close 11.16, 1 stories17 Apr 2026: news score 50, close 16.01, 3 stories24 Apr 2026: news score 50, close 14.8, 2 stories5001 May 2026: news score 50, close 15.5, 2 stories08 May 2026: news score 50, close 13.28, 2 stories15 May 2026: news score 50, close 13.51, 2 stories22 May 2026: news score 50, close 11.92, 1 stories5029 May 2026: news score 50, close 11.94, 1 stories05 Jun 2026: news score 50, close 9.95, 1 stories26 Jun 2026: news score 52, close 10.0, 4 stories03 Jul 2026: news score 50, close 9.49, 4 stories5010 Jul 2026: news score 50, close 9.87, 6 stories17 Jul 2026: news score 50, close 11.53, 9 stories24 Jul 2026: news score 50, close 12.5, 9 stories31 Jul 2026: news score 51, close 13.0, 20 stories5107 Aug 2026: news score 50, close 13.28, 30 stories14 Aug 2026: news score 54, close 13.25, 38 stories21 Aug 2026: news score 52, close 13.7, 37 stories28 Aug 2026: news score 53, close 13.82, 34 stories5304 Sep 2026: news score 51, close 15.01, 22 stories11 Sep 2026: news score 57, close 15.21, 24 stories18 Sep 2026: news score 52, close 15.74, 17 stories52 Price index 265.6 173.9 82.3 News score 100 50 0
27 Mar23 Jun18 Sep
Weekly close, indexedSentiment score
26-week price+143.7%latest close 15.74
News score change+2first to latest comparable week
One-week response+1.3%Price digesting
Fair-value position+158.5%Materially above fair value
WeekNews scoreCloseWeekly move
18 Sep 202652USD 15.74+3.5%
11 Sep 202657USD 15.21+1.3%
04 Sep 202651USD 15.01+8.6%
28 Aug 202653USD 13.82+0.9%
21 Aug 202652USD 13.7+3.4%
14 Aug 202654USD 13.25-0.2%
07 Aug 202650USD 13.28+2.2%
31 Jul 202651USD 13.0+4.0%
Provisional evidence

News subjects

What is shaping the score

Market update
Market update508 stories · 47%
Earnings514 stories · 24%
Analyst action763 stories · 18%
Guidance501 stories · 6%
Deals and strategy501 stories · 6%

Source mix

Where the evidence comes from

21/100 independence
Stock Titan504 stories · 24%
Investing.com653 stories · 18%
www.marketscreener.com502 stories · 12%
Eastern Progress781 stories · 6%
Kalkine Media611 stories · 6%
simplywall.st421 stories · 6%
Simply Wall Street471 stories · 6%

Recurring subjects

Subjects appearing most often

Current evidence
Life Sciences11Financial Markets6Earnings5Finance2Mergers And Acquisitions1IPO1

Earlier readings

How the score has changed

44 comparable readings · 162 days
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
Comparable move+051 to 51 · Broadly stable
Observed range50–5850 is the neutral baseline
Evidence depth15stories at latest stored reading · +13
Confidence18/100Provisional · -11
12 Apr50 neutral21 Sep 13:47
ConstructiveBalanced or withheldCautious

Changes in the stored score

Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.

ObservedScoreMoveConfidenceStoriesStatus
21 Sep 13:4751-118/100 (-1)15 (-2)Provisional
18 Sep 23:5952-119/100 (-2)17 (-1)Provisional
16 Sep 23:5953+021/100 (-1)18 (+1)Provisional
15 Sep 23:5953-422/100 (-8)17 (-7)Provisional
11 Sep 23:5957-130/100 (-4)24 (+1)Provisional
10 Sep 23:5958+234/100 (+2)23 (-1)Provisional
08 Sep 23:5956+532/100 (+11)24 (+2)Provisional
05 Sep 23:5951-221/100 (-10)22 (-12)Provisional

Source headlines

The news behind the score

Showing 1-17 of 17

Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.

#1—Not directional
Stock TitanDirect company coverageScored from headline

Adlai Nortye (NASDAQ: ANL) director lines up ADS sale

Published
18 Sep 2026 15:10
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 0.5d old
Duplicates
1 consolidated
#2—Not directional
Investing.com CanadaDirect company coverageStored article

Adlai Nortye at Morgan Stanley global healthcare conference: RAS push By Investing.com

Adlai Nortye presented its oncology strategy at the Morgan Stanley 24th Annual Global Healthcare Conference, focusing on RAS-targeted drugs and combination therapies. The company highlighted two lead programs, AN9025 (an oral pan-RAS(ON) inhibitor) and AN4035 (a first-in-class ADC with a RAS inhibitor payload), showing promising preclinical data and early human clinical signs. With a robust cash cushion of $232 million, providing runway through 2028, Adlai Nortye plans significant clinical updates in 2027 to demonstrate best-in-class potential and pursue combination therapy strategies, especially for pancreatic and lung cancers.

EarningsLife Sciences
Published
16 Sep 2026 17:00
News subject
Earnings
Why this score
The headline reports news without a clear direction
Company focus
Shared story · 78%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 2.4d old
Duplicates
1 consolidated
#3—Not directional
Stock TitanDirect company coverageScored from headline

Adlai Nortye Group Ltd. SEC Filing (Sep 16, 2026)

Published
16 Sep 2026 10:10
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 2.7d old
Duplicates
1 consolidated
#4—Not directional
Simply Wall St.Direct company coverageScored from headline

4.8x P B? Adlai Nortye Group (ANL) On Its AN4035 Trial Progress

Published
15 Sep 2026 17:12
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 3.4d old
Duplicates
2 consolidated
#5—Not directional
Stock TitanDirect company coverageScored from headline

Adlai Nortye (NASDAQ: ANL) readies new offerings as holders plan a large ADS resale

Published
11 Sep 2026 17:22
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 7.4d old
Duplicates
1 consolidated
#677Tone
Investing.comDirect company coverageStored article

Jefferies initiates Adlai Nortye stock with buy rating on drug potential

Jefferies has initiated coverage on Adlai Nortye Ltd. (NASDAQ:ANL) with a buy rating and a $31.00 price target, citing the strong potential of its AN9025 drug candidate, which it believes could be a best-in-class pan-RAS inhibitor. The firm anticipates positive Phase 1 data for AN9025 and also sees long-term optionality in AN4035. Other analysts, including Lucid Capital Markets and Cantor Fitzgerald, have also recently started coverage with positive ratings, highlighting the company's progress in clinical trials and expansion of its Scientific Advisory Board.

Financial MarketsLife Sciences
Published
10 Sep 2026 12:29
News subject
Analyst action
Why this score
Analyst upgrade, Buy Rating
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
High · 58/100
30-day weight
54% of the score · 8.6d old
Duplicates
2 consolidated
#7—Not directional
Investing.comDirect company coverageStored article

Adlai Nortye doses first patient in AN4035 cancer trial

Adlai Nortye Group Ltd. has initiated a global Phase I clinical trial for its cancer drug candidate AN4035, with the first patient dosed in Australia. The trial targets CEACAM5-enriched RAS-addicted solid tumors, and the company has received a "Study-May-Proceed" letter from the FDA to expand the trial into the United States. Adlai Nortye expects to report full Phase Ia data in the second half of 2027.

Life Sciences
Published
08 Sep 2026 13:40
News subject
Guidance
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 10.5d old
Duplicates
1 consolidated
#8—Not directional
GlobeNewswireDirect company coverageStored article

Adlai Nortye Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-in-Class Pan-RAS(ON) Inhibitor-Based ADC

Adlai Nortye announced that the first patient has been dosed with AN4035 in Australia for a global Phase I trial in patients with CEACAM5-enriched RAS-addicted solid tumors. The company also received U.S. FDA IND clearance, allowing expansion of the trial into the United States. AN4035 is a first-in-class ADC designed to deliver a potent pan-RAS(ON) inhibitor selectively to tumors, addressing challenges of systemic toxicity and the need for novel ADC payloads.

Life Sciences
Published
08 Sep 2026 11:00
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 10.7d old
Duplicates
2 consolidated
#975Tone
Investing.comDirect company coverageStored article

Lucid Capital Markets initiates Adlai Nortye stock with buy rating

Lucid Capital Markets initiated coverage on Adlai Nortye Ltd. (NASDAQ:ANL) with a buy rating and a $49.00 price target, citing significant upside potential from the current stock price of $15.01. The investment thesis is primarily based on AN9025, an oral pan-RAS(ON) inhibitor, and its differentiated preclinical profile. The firm's valuation is anchored by AN9025's potential in first-line metastatic PDAC and previously treated RAS-mutant NSCLC, projecting approximately $2.46 billion in combined risk-adjusted worldwide peak sales.

Financial MarketsLife Sciences
Published
08 Sep 2026 10:59
News subject
Analyst action
Why this score
Analyst upgrade, Buy Rating, Positive valuation view
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 55/100
30-day weight
34.1% of the score · 10.7d old
Duplicates
1 consolidated
#10—Not directional
MoomooDirect company coverageStored article

Adlai Nortye's KRAS Opportunity Further Validated by GSK-Hutchmed Deal, Oppenheimer Says

Oppenheimer highlighted that GSK's $1.4 billion deal with Hutchmed for a KRAS G12C inhibitor further validates Adlai Nortye's promising KRAS opportunity. Adlai Nortye is developing AN2025, a KRAS G12D inhibitor, which Oppenheimer believes could have significant potential given the larger market for G12D mutations compared to G12C. The firm maintains an Outperform rating and a $30 price target for Adlai Nortye.

Financial MarketsLife SciencesMergers And Acquisitions
Published
05 Sep 2026 09:59
News subject
Deals and strategy
Why this score
Positive financial language
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 13.7d old
Duplicates
1 consolidated
#1142Tone
simplywall.stDirect company coverageScored from headline

Have Insiders Sold Adlai Nortye Group Shares Recently?

Published
28 Aug 2026 11:05
News subject
Market update
Why this score
Institutional or insider selling
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Low · 30/100
30-day weight
<0.1% of the score · 21.6d old
Duplicates
1 consolidated
#1261Tone
Kalkine MediaDirect company coverageStored article

Adlai Nortye CFO Ye Xiaofeng Reports Sale of 11,667 ADS in Two Open-Market Transactions

Adlai Nortye Group Ltd. (NASDAQ:ANL) CFO Ye Xiaofeng sold a total of 11,667 American Depositary Shares (ADS) in two open-market transactions on August 24 and August 26, 2026. The sales were primarily to optimize the reporting person's tax and liquidity management following RSU vesting in April 2026, with tax obligations for the vesting previously met using out-of-pocket cash. After these sales, Ye Xiaofeng directly holds 147,757 ADS.

EarningsFinanceFinancial MarketsLife Sciences
Published
27 Aug 2026 16:30
News subject
Earnings
Why this score
Business expansion
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 40/100
30-day weight
11.3% of the score · 22.4d old
Duplicates
1 consolidated
#13—Not directional
Stock TitanDirect company coverageScored from headline

Adlai Nortye (ANL) sets vote on new share authorization

Published
26 Aug 2026 13:07
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 23.6d old
Duplicates
1 consolidated
#14—Not directional
Simply Wall StreetDirect company coverageStored article

Adlai Nortye Group (Nasdaq:ANL) - Stock Analysis

This Simply Wall St stock analysis for Adlai Nortye Group (ANL) provides a comprehensive overview, including company financials, growth prospects, and identified risks such as shareholder dilution and volatile share price. Despite past earnings growth, future earnings are forecast to decline, and the company remains unprofitable. The report also details recent news, including clinical trial updates for AN9025 and AN0025, board changes, and funding announcements.

EarningsIPOLife Sciences
Published
23 Aug 2026 05:44
News subject
Earnings
Why this score
Operating deterioration, Operating growth, Dilution risk
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 26.9d old
Duplicates
1 consolidated
#1578Tone
Eastern ProgressDirect company coverageStored article

Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's What You Should Know

Adlai Nortye Ltd. Sponsored ADR (ANL) has been upgraded to a Zacks Rank #2 (Buy), reflecting an upward trend in its earnings estimates. This upgrade suggests an improved earnings outlook for the company, which often correlates with a favorable impact on stock price. The Zacks system highlights the importance of earnings estimate revisions for predicting near-term stock movements, with ANL's upgrade placing it in the top 20% of Zacks-covered stocks.

EarningsFinanceFinancial MarketsLife Sciences
Published
22 Aug 2026 18:44
News subject
Analyst action
Why this score
Analyst upgrade, Operating growth
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 53/100
30-day weight
0.6% of the score · 27.3d old
Duplicates
1 consolidated
#16—Not directional
www.marketscreener.comDirect company coverageStored article

ANL: Static price chart | Adlai Nortye Group Ltd. | US00704R1095

This page on MarketScreener provides a static price chart for Adlai Nortye Group Ltd. (ANL), a biotechnology and medical research company listed on Nasdaq under the stock symbol US00704R1095. It also includes recent news about the company's name and registered office address changes, along with various financial metrics and analytical tools offered by the platform.

Financial MarketsLife Sciences
Published
22 Aug 2026 00:43
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 28.1d old
Duplicates
1 consolidated
#17—Not directional
www.marketscreener.comDirect company coverageStored article

Adlai Nortye Ltd. will Change its Name to Adlai Nortye Group Ltd

Adlai Nortye Ltd. announced that effective August 21, 2026, it will officially change its name to Adlai Nortye Group Ltd. This change was published on MarketScreener and S&P Capital IQ. The article also provides a company profile, recent news, and financial data for Adlai Nortye Ltd.

EarningsLife Sciences
Published
21 Aug 2026 14:40
News subject
Earnings
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 28.5d old
Duplicates
1 consolidated

Earlier company news

ANL news archive

68 older headlines

Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.

Older news is kept in the archive

There are 68 older ANL headlines. Open one page at a time when you need them.

Open older archive

Provider matches checked

Provider mentions not used in the score

4 not scored

A news provider linked these stories to ANL, but the headline and available text are not mainly about Adlai Nortye Ltd. American Depositary Shares. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.

Provider mentions are kept separate

Open the list to see which provider matches were checked and left out of ANL sentiment.

Open provider mentions

How the page works

How to read the score

The score shows direction

It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.

Confidence is separate

Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.

Price is confirmation

Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.

What the page does

It measures news already published. It is not a forecast, recommendation or price target.

Evidence context